Autolus Therapeutics plc Revenue
Autolus Therapeutics plc (AUTL) reported Revenue of $8.98 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2025-05-08
- Autolus Therapeutics plc revenues for the quarter ending 2025-03-31 was $8.98M, a 10.99% decline year-over-year.
- Autolus Therapeutics plc revenues for the quarter ending 2024-03-31 was $10.09M.
- Autolus Therapeutics plc revenues for the quarter ending 2021-03-31 was $269.00K, a 20.41% decline year-over-year.
- Autolus Therapeutics plc revenues for the quarter ending 2020-06-30 was $293.00K, a 13.31% decline year-over-year.
- Autolus Therapeutics plc revenues for fiscal 2024 was $10.12M, a 496.00% increase from fiscal 2023.
- Autolus Therapeutics plc revenues for fiscal 2023 was $1.70M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2025-03-31 | $8.98M 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $10.12M 10-K · filed 2025-03-20 | |||
| 2024-03-31 | $10.09M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $1.70M 10-K · filed 2025-03-20 | |||
| 2021-03-31 | $269.00K 6-K · filed 2021-05-06 | |||
| 2020-06-30 | $293.00K 6-K · filed 2020-08-06 | $631.00K 6-K · filed 2020-08-06 | $940.00K derived: sum of 3 quarters · filed 2021-05-06 | $1.24M derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-03-31 | $338.00K 6-K · filed 2021-05-06 | $647.00K derived: sum of 2 quarters · filed 2021-05-06 | $944.00K derived: sum of 3 quarters · filed 2021-05-06 | $1.28M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $309.00K derived: 20-F 12 month − 6-K 9 month · filed 2020-03-03 | $606.00K derived: sum of 2 quarters · filed 2020-03-03 | $944.00K derived: sum of 3 quarters · filed 2020-08-06 | $2.91M 20-F · filed 2020-03-03 |
| 2019-09-30 | $297.00K 6-K · filed 2019-11-07 | $635.00K derived: sum of 2 quarters · filed 2020-08-06 | $2.60M 6-K · filed 2019-11-07 | $2.90M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-06-30 | $338.00K 6-K · filed 2020-08-06 | $2.30M 6-K · filed 2020-08-06 | $2.60M derived: sum of 3 quarters · filed 2020-08-06 | $2.90M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.96M 6-K · filed 2020-05-07 | $2.26M derived: sum of 2 quarters · filed 2020-05-07 | $2.57M derived: sum of 3 quarters · filed 2020-05-07 | $3.01M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $296.00K 20-F · filed 2020-03-03 | $603.00K derived: sum of 2 quarters · filed 2020-03-03 | $1.05M derived: sum of 3 quarters · filed 2020-03-03 | |
| 2018-09-30 | $307.00K 6-K · filed 2019-11-07 | $750.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.18M 6-K · filed 2019-11-07 | $1.41M 20-F · filed 2020-03-03 |
| 2018-06-30 | $443.00K 6-K · filed 2019-08-08 | $869.00K 6-K · filed 2019-08-08 | ||
| 2017-12-31 | $231.00K 20-F · filed 2019-02-25 | |||
| 2017-09-30 | $1.69M 20-F · filed 2020-03-03 | |||
| 2016-09-30 | $1.21M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |